4 active not recruiting, 4 completed, 4 recruiting, 2 withdrawn. 15 Phase 2, 8 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Active not recruiting 4, Completed 4, Recruiting 4, Withdrawn 2, Terminated 1 |
| Phase 1 | 8 | Completed 3, Recruiting 2, Withdrawn 2, Terminated 1 |
Follow NHL: new trials by email Literature Review of NHL trials Research Report on NHL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CMOP±R in the Treatment of Untreated Non-Hodgkin's Lymphoma CMOP±R - NHL | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 197 | 2024-07-08 | 2026-09-09 |
| IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers IDP-023, Rituximab, Daratumumab - NHL, Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Indapta Therapeutics, INC. | 128 | 2023-10-25 | 2025-06-03 |
| Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies Vysis LSI MYC Break Apart Rearrangement Probe Kit, Venetoclax, VIP152 - Lymphoma, Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 8 | 2023-04-05 | 2026-02-23 |
| Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCL ARI-0001, Axi-cel - NHL, DLBCL - Diffuse Large B Cell Lymphoma | Phase 2 | Active not recruiting | University Medical Center Groningen | 340 | 2022-10-18 | 2026-10-05 |
| A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL BN102 - CLL/SLL, NHL | Phase 1 / Phase 2 | Withdrawn | BioNova Pharmaceuticals (Shanghai) LTD. | 2022-07-01 | 2023-03-24 | |
| Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients IM19 CAR-T Cells - NHL | Phase 1 / Phase 2 | Recruiting | Beijing Immunochina Medical Science & Technology Co., Ltd. | 52 | 2020-06-04 | 2020-12-08 |
| Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma Rituximab, Copanlisib, Bone Marrow Aspiration/Biopsy - Follicular Lymphoma, Non-Hodgkin's Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 33 | 2019-08-22 | 2026-03-03 |
| Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma DA-EPOCH, Rituximab, CHOP - Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 132 | 2019-08-05 | 2026-11-09 |
| A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant Hyperbaric oxygen - AML, NHL | Phase 2 | Active not recruiting | University of Rochester | 64 | 2019-02-28 | 2026-07-20 |
| The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL Atezolizumab - NHL, DLBCL | Phase 2 | Active not recruiting | Stichting Hemato-Oncologie voor Volwassenen Nederland | 109 | 2018-08-30 | 2026-09-23 |
| Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL Veltuzumab and 90Y-Epratuzumab Tetraxetan, 90Y-epratuzumab tetraxetan, veltuzumab - Non Hodgkin's Lymphoma, NHL | Phase 1 / Phase 2 | Withdrawn | Gilead Sciences | 2010-05-01 | 2021-08-18 | |
| Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL veltuzumab - NHL, Lymphoma, Non-Hodgkin | Phase 1 / Phase 2 | Completed | Gilead Sciences | 32 | 2008-01-01 | 2021-08-16 |
| Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft Naive T-cell Depleted Stem Cell Transplant, Stem Cell Transplant No Manipulation, Isolex device from Baxter - ALL, ANLL | Phase 1 / Phase 2 | Terminated | Duke University | 15 | 2007-07-01 | 2013-11-25 |
| Safety Study of NHL With 90Y-hLL2 IgG 90Y-hLL2 - NHL, B-cell NHL | Phase 1 / Phase 2 | Completed | Gilead Sciences | 59 | 2002-08-01 | 2021-08-16 |
| Allogeneic Transplantation From Related Haploidentical Donors non-myeloablative hematopoietic cell transplantation, Anti-Thymocyte Globulin, Cyclosporine - Blood Cancer, Leukemia | Phase 2 | Completed | Stanford University | 16 | 2000-08-01 | 2019-12-04 |
Lymphoma, Non-Hodgkin (7) · Hematologic Neoplasms (3) · Dendritic Cell Sarcoma, Interdigitating (2) · Hodgkin Disease (2) · Leukemia (2) · Lymphoma, Follicular (2) · Lymphoma, Large B-Cell, Diffuse (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Graft vs Host Disease (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Prolymphocytic (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Multiple Myeloma (1)
Hemic and Lymphatic Diseases (11) · Neoplasms by Histologic Type (11) · Lymphatic Diseases (10) · Neoplasms (10) · Immune System Diseases (9) · Immunoproliferative Disorders (9) · Lymphoproliferative Disorders (9) · Lymphoma (8) · Hematologic Diseases (7) · Leukemia (3) · Leukemia, Lymphoid (3) · Neoplasms by Site (3) · Disease Attributes (2) · Histiocytic Disorders, Malignant (2) · Histiocytosis (2)
Rituximab (3) · Biopsy (2) · Cyclophosphamide (2) · Electrocardiography (2) · Positron-Emission Tomography (2) · fludarabine (2) · veltuzumab (2) · Acetaminophen (1) · Antilymphocyte Serum (1) · Cyclosporine (1) · Diphenhydramine (1) · EPOCH protocol (1) · Echocardiography (1) · Granulocyte Colony-Stimulating Factor (1) · Hydrocortisone (1)
Gilead Sciences (3) · National Cancer Institute (NCI) (3) · Beijing Immunochina Medical Science & Technology Co., Ltd. (1) · BioNova Pharmaceuticals (Shanghai) LTD. (1) · Duke University (1) · Indapta Therapeutics, INC. (1) · Stanford University (1) · Stichting Hemato-Oncologie voor Volwassenen Nederland (1) · The First Affiliated Hospital of Soochow University (1) · University Medical Center Groningen (1) · University of Rochester (1)
United States (8) · China (3) · Netherlands (2) · Belgium (1) · France (1) · Germany (1)
Christopher J Melani, M.D. (2) · William Wegener, MD, PhD (2) · Haiwen Huang (1) · M. Nijland, PhD/MD (1) · Mitchell Horwitz, MD (1) · Omar Aljitawi (1) · Rahul Lakhotia, M.B.B.S. (1) · Robert Lowsky (1) · Weili Zhao, Prof. (1) · William A Wegener, MD, PhD (1) · Yuqin Song, MD, PhD (1)
PMID 21173095, PMID 26389849, PMID 37882668, PMID 40249860, PMID 40802906
2017 (1)